Table 4.
Delayed increase in peripheral blood cell counts for acute myeloid leukemia (AML) patients with stable disease during treatment with all-trans retinoic acid (ATRA), valproic acid and low-dose cytarabine; a comparison of pretreatment/early treatment values versus maximal levels
| Platelet | Neutrophil | Erythrocyte | |||
|---|---|---|---|---|---|
|
Patient |
Before or during the first 14 days |
Highest value during treatment |
Before or during the first 14 days |
Highest value during treatment |
Transfusion independent > two months |
| SD1 |
12 |
49 (90) |
0.1 |
0.7 (102) |
yes |
| SD2 |
22 |
64 (273) |
0.1 |
0.8 (77) |
yes |
| SD3 |
< 5 |
79 (55) |
0.4 |
0.4 (74) |
- |
| SD4 |
103 |
302 (51) |
0.5 |
0.2 (126) |
- |
| SD5 |
19 |
51 (136) |
< 0.1 |
0.3 (67) |
yes |
| SD6 |
55 |
81 (106) |
< 0.1 |
0.2 (112) |
- |
| SD7 |
18 |
30 (15) |
9.8 |
7.2 (27) |
- |
| SD8 |
48 |
98 (40) |
3.8 |
8.2 (473) |
- |
| SD9 | 28 | 96 (141) | 2.9 | 1.8 (49) | - |
The values before treatment represent the lowest value during this time. The highest value represents the value registered after the first 14 days of treatment, and the parenthesis gives the day after start of treatment when this value was registered. The units for both platelet and neutrophil counts are × 109 /L.